GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -59.48% | 87.70% | -639.60% | 89.68% | -3,787.76% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.43% | -99.80% | 11,717.69% | -99.47% | 22,620.33% |
| Change in Net Operating Assets | -35.76% | -79.85% | 330.70% | -30.28% | 58.17% |
| Cash from Operations | -72.61% | 38.62% | -9.36% | -22.00% | -36.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -87.02% | -- | -100.00% | -29.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -92.58% | -0.05% | 277.12% | -80.48% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -69.41% | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.52% | -44.85% | 750.05% | -83.38% | 854.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -287.64% | -50.70% | 258.67% | -194.31% | 280.52% |